For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Boehringer Ingelheim Obtains Approval for MicadisPlus in EU
June 17, 2002
- Fuso: Stiffer Competition Squeezes Profits
June 17, 2002
- REGULATORY NEWS IN BRIEF
June 17, 2002
- Sanofi-Synthelabo Reports Hypotensive Effects of Irbesartan
June 17, 2002
- Nippon Chemiphar: New Gout Treatment GL to Remarkably Boost Sales, Profits
June 17, 2002
- If Generics Were 60% Cheaper, 22% of Patients Would Choose Them: Survey
June 17, 2002
- Enrollment Completed for Major Int'l Stroke Prevention Trial: Sanofi-Sythelabo
June 17, 2002
- Nissui: Sales, Profits Down Due to Slump of Diagnostics
June 17, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 17, 2002
- Fondaparinux Prevents VTE after Hip Replacement Surgery
June 17, 2002
- Morishita Jintan: 15.6% Drop in Sales, Net Loss of \953 Mil.
June 17, 2002
- JSC to Draft Manual for Antibacterial Clinical Trials in Specific Disease States
June 17, 2002
- Zoledronate Delays Onset of Cancer-related Bone Complications: Novartis
June 17, 2002
- Meiji Seika Kaisha: Drug Sales Down 6.1% to \110.7 Bil.
June 17, 2002
- Speed, Quality, Costs Are Main Problems for Clinical Trials in Japan
June 17, 2002
- Effects of Glivec on GIST Presented
June 17, 2002
- Kirin: 1st Qtr Drug Sales Up 4.9% to \9.2 Bil.
June 17, 2002
- Tokyo Area Genomic Network Promotion Council Inaugurated
June 17, 2002
- Pharmacia Reports PIII Results on Eplerenone
June 17, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
June 17, 2002
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…